08:36 AM EDT, 09/10/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Wednesday that the US Food and Drug Administration accepted its new drug application for relacorilant to treat patients with platinum-resistant ovarian cancer and set a Prescription Drug User Fee Act review date of July 11, 2026 for the application.

The company said the filing is supported by results from a phase 3 trial and a phase 2 study, which indicated that relacorilant combined with nab-paclitaxel "improved progression-free and overall survival" compared with nab-paclitaxel alone.